Short answer
Olema Pharmaceuticals, Inc. (OLMA) filed its Q3 2025 10-Q quarterly report on Nov 10, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$42M
- −22.2% YoY · +3.6% QoQ
- EPS (diluted)
- −$0.49
- +30.0% YoY · +3.9% QoQ
Source: XBRL data from the Olema Pharmaceuticals, Inc. (OLMA) Q3 2025 10-Q on SEC EDGAR. USD.
Olema Pharmaceuticals, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New regulatory risk: Loan Agreement amendments in 2025 lowered interest to 6.0% minimum, extended draw period to Jan 15, 2026, increasing debt service complexity
- Material update financial risk: Net loss widened to $42.2M in Q3 2025 from $34.6M in Q3 2024, reflecting escalating R&D and operational expenses
- Legal/compliance risk: Potential default events under Loan Agreement include delisting, material adverse changes, accelerating repayment and impacting liquidity
- Operational risk: Heavy dependence on clinical development success of lead candidate palazestrant; failure delays commercialization and future cash flows
- Financial concentration risk: As of Sep 30, 2025, only $3.0M drawn from $100M Credit Facility, highlighting selective capital access amid uncertain funding environment
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Olema Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.